UBS Group Portfolio holdings
UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Strategy Inc
MSTR
|
+$1.21B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$855M |
| 3 |
Microsoft
MSFT
|
+$810M |
| 4 |
Advanced Micro Devices
AMD
|
+$805M |
| 5 |
Boeing
BA
|
+$739M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$561M |
| 2 |
Amneal Pharmaceuticals
AMRX
|
+$169M |
| 3 |
Eli Lilly
LLY
|
+$161M |
| 4 |
Unity
U
|
+$158M |
| 5 |
State Street SPDR S&P Regional Banking ETF
KRE
|
+$127M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.49% |
| 2 | Financials | 9.06% |
| 3 | Consumer Discretionary | 7.01% |
| 4 | Healthcare | 6.25% |
| 5 | Industrials | 6.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
7001
Next Technology
NXTT
$4.68M
| $79.1K | ﹤0.01% |
+162
| New | +$55.4K |
|
7002
DLH Holdings
DLHC
$70.1M
| $78.9K | ﹤0.01% |
9,822
+5,811
| +145% | +$48.6K |
|
|
HIND
7003
Vyome Holdings
HIND
$15.2M
| $78.8K | ﹤0.01% |
+177
| New | +$93.4K |
|
7004
Catalyst Bancorp
CLST
$70M
| $78.7K | ﹤0.01% |
6,689
+701
| +12% | +$8.1K |
|
|
SCNI
7005
Scinai Immunotherapeutics
SCNI
$1.27M
| $78.6K | ﹤0.01% |
23,488
+23,458
| +78,193% | +$80.6K |
|
7006
Fidelity Fundamental Large Cap Core ETF
FFLC
$1.26B
| $78.6K | ﹤0.01% |
+1,712
| New | +$79.9K |
|
7007
Air T
AIRT
$86.1M
| $78.5K | ﹤0.01% |
3,934
-966
| -20% | -$17.8K |
|
|
BSIIU
7008
DELISTED
Black Spade Acquisition II Co Unit
BSIIU
| $78.4K | ﹤0.01% |
7,805
-5,010
| -39% | -$50.1K |
|
7009
Harvard Bioscience
HBIO
$29.1M
| $78.4K | ﹤0.01% |
3,717
+1,645
| +79% | +$37.8K |
|
7010
RCM Technologies
RCMT
$207M
| $78.2K | ﹤0.01% |
3,531
+2,353
| +200% | +$52.4K |
|
7011
Estrella Immunopharma
ESLA
$31.1M
| $78.2K | ﹤0.01% |
65,167
+58,644
| +899% | +$59.1K |
|
7012
Invesco KBW Premium Yield Equity REIT ETF
KBWY
$310M
| $77.9K | ﹤0.01% |
4,347
+2,011
| +86% | +$39.8K |
|
7013
Indonesia Energy Corp
INDO
$42.6M
| $77.7K | ﹤0.01% |
+27,951
| New | +$98.1K |
|
|
XCH
7014
XCHG Ltd
XCH
$24.9M
| $77.6K | ﹤0.01% |
+38,237
| New | +$606K |
|
|
NETD
7015
DELISTED
Nabors Energy Transition Corp II
NETD
| $77.5K | ﹤0.01% |
7,178
+7,100
| +9,103% | +$76.1K |
|
7016
Xos
XOS
$37.7M
| $77.5K | ﹤0.01% |
23,920
-4,111
| -15% | -$17.2K |
|
7017
Neuropace
NPCE
$505M
| $77.3K | ﹤0.01% |
6,910
+2,825
| +69% | +$24.6K |
|
|
RANGU
7018
Range Capital Acquisition Corp Units
RANGU
| $77.2K | ﹤0.01% |
+7,700
| New | +$77.2K |
|
7019
First Trust Nasdaq Oil & Gas ETF
FTXN
$157M
| $77K | ﹤0.01% |
2,678
-2,281
| -46% | -$68.6K |
|
|
ZSEP
7020
Innovator Equity Defined Protection ETF - 1 Yr September
ZSEP
$123M
| $76.5K | ﹤0.01% |
+3,049
| New | +$76.2K |
|
|
ADAP
7021
DELISTED
Adaptimmune Therapeutics
ADAP
| $76.4K | ﹤0.01% |
141,744
+139,927
| +7,701% | +$102K |
|
|
GRI
7022
GRI Bio
GRI
$2.6M
| $76.4K | ﹤0.01% |
194
+43
| +28% | +$14.7K |
|
7023
Gain Therapeutics
GANX
$78.1M
| $76.1K | ﹤0.01% |
35,227
+26,772
| +317% | +$53.7K |
|
7024
First Trust Intermediate Duration Investment Grade Corporate ETF
FIIG
$649M
| $76.1K | ﹤0.01% |
+3,720
| New | +$77.6K |
|
|
CAPT
7025
DELISTED
Captivision
CAPT
| $75.9K | ﹤0.01% |
107,517
+105,841
| +6,315% | +$129K |
|
Similar funds
UBS Group's Q4 2024 Portfolio in Review
As of Q4 2024, UBS Group held 10,816 positions worth $541B, up 18% from $459B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
UBS Group deployed $80.6B of net new capital in Q4 2024, opening 1,382 new positions and adding to 6,044 existing holdings. Its largest new stake was Primo Brands: 1,234,826 shares worth $38M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was UnitedHealth, an estimated $561M trimmed.
- UBS Group's largest Q4 2024 buy was Primo Brands: 1,234,826 shares worth $38M.
- UBS Group added most to Strategy Inc in Q4 2024, an estimated $1.21B increase.
- UBS Group's biggest Q4 2024 reduction was UnitedHealth, cutting an estimated $561M.
- UBS Group fully exited CATALENT, INC. in Q4 2024, selling an estimated $86M.
- UBS Group's ten largest holdings make up 16% of its $541B portfolio in Q4 2024.
- UBS Group opened 1,382 new positions and closed 943 in Q4 2024.
- UBS Group's portfolio value rose 18% quarter-over-quarter to $541B.
Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.